MedTrace Logo

CKD-330 Phase 3 Trial in Amlodipine Non-responder

NCT02586311 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2016-10-06

No results posted yet for this study

Summary

Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

Conditions

Interventions

DRUG

CKD-330 16/5mg

Once a day, 8 weeks

DRUG

Amlodipine 5mg Placebo

Once a day, 8 weeks

DRUG

CKD-330 16/5mg Placebo

Once a day, 8 weeks

DRUG

Amlodipine 5mg

Once a day, 8 weeks

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Chang Gyu Park, M.D, Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-08-31
Completion
2016-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02586311 on ClinicalTrials.gov